Provided by Tiger Trade Technology Pte. Ltd.

BioVie Inc

1.93
+0.02001.05%
Post-market: 1.950.0200+1.04%16:34 EDT
Volume:170.35K
Turnover:333.69K
Market Cap:16.31M
PE:-0.63
High:2.02
Open:1.92
Low:1.91
Close:1.91
52wk High:3.79
52wk Low:0.8200
Shares:8.45M
Float Shares:8.41M
Volume Ratio:0.58
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0500
EPS(LYR):-3.0500
ROE:-150.76%
ROA:-79.06%
PB:1.59
PE(LYR):-0.63

Loading ...

BRIEF-Biovie Files To Offer Up To $300 Million In Securities - SEC Filing

Reuters
·
Jun 19

BioVie Files $300 Million Mixed Shelf

MT Newswires Live
·
Jun 19

BioVie files $300M mixed securities shelf

TIPRANKS
·
Jun 19

BioVie - Files to Offer up to $300 Mln in Securities - SEC Filing

THOMSON REUTERS
·
Jun 19

BioVie posts corporate presentation spotlighting bezisterim longevity-focused therapy pipeline

Reuters
·
Jun 02

BioVie to host live investor webinar with CEO presentation and Q&A

Reuters
·
May 27

Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2

GlobeNewswire
·
May 27

BioVie announces full enrollment of ADDRESS-LC trial of bezisterim

TIPRANKS
·
May 26

BioVie completes enrollment in Phase 2 long COVID trial of bezisterim, targets late summer 2026 data

Reuters
·
May 26

BioVie Announces Full Enrollment of the Address-Lc Trial of Bezisterim for the Treatment of Neurological Symptoms Associated With Long Covid

THOMSON REUTERS
·
May 26

BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

GlobeNewswire
·
May 26

BioVie Announces Completion of Phase 2 Sunrise-Pd Trial in Early-Stage Parkinson’s Disease

THOMSON REUTERS
·
May 18

BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease

GlobeNewswire
·
May 18

BioVie Q3 FY26 net loss widens to $5.3 million; operating expenses climb to $5.4 million

Reuters
·
May 12

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

GlobeNewswire
·
Apr 27

BioVie SUNRISE-PD bezisterim abstract accepted for presentation at 2026 AAN meeting

Reuters
·
Apr 14

BioVie publishes corporate presentation on bezisterim pipeline catalysts in Parkinson’s, Long Covid

Reuters
·
Apr 02